DD1

• Description:

  DD1, a proteasome inhibitor, targets Bax activation and P70S6K degradation during acute myeloid leukemia (AML) apoptosis. DD1 induces apoptosis in the caspase-dependent manner. DD1 induces mitochondrial membrane depolarization and Bad dephosphorylation[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H301

• Target:

  Apoptosis; Proteasome; Ribosomal S6 Kinase (RSK)

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; MAPK/ERK Pathway; Metabolic Enzyme/Protease

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/dd1.html

• Purity:

  99.40

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C1C(N)=C(C2=CC=C(OC)C(N)=C2)OC3=CC=CC=C13

• Molecular Formula:

  C16H14N2O3

• Molecular Weight:

  282.29

• Precautions:

  H301

• References & Citations:

  [1]Marion Piedfer, et al. p70S6 kinase is a target of the novel proteasome inhibitor 3,3'-diamino-4'-methoxyflavone during apoptosis in human myeloid tumor cells. Biochim Biophys Acta. 2013 Jun;1833 (6) :1316-28.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  P70S6K

• CAS Number:

  187585-11-1